Farrokh-Eslamlou Nika, Momtaz Saeideh, Niknejad Amirhossein, Hosseini Yasamin, Mahdaviani Parvin, Ghasemnejad-Berenji Morteza, Abdolghaffari Amir Hossein
Department of Toxicology & Pharmacology, Faculty of Pharmacy, Tehran Medical Sciences, Islamic Azad University, No. 99, Yakhchal, Gholhak, Shariati St., P. O. Box: 19419-33111, Tehran, Iran.
GI Pharmacology Interest Group (GPIG), Universal Scientific Education and Research Network (USERN), Tehran, Iran.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):7061-7070. doi: 10.1007/s00210-024-03088-6. Epub 2024 Apr 21.
Cisplatin (Cis) is a platinum-based antineoplastic drug used in various types of cancers. This drug can induce nephrotoxicity as a cause of acute kidney injury (AKI) by inducing oxidative stress and inflammation. Empagliflozin (Empa) is a newly developed inhibitor of sodium-glucose cotransporter-2 (SGLT2) approved as an antidiabetic medication for patients with type 2 diabetes mellitus. In addition to its blood glucose-lowering effect, Empa has been shown to exert anti-inflammatory and anti-oxidant properties. The current study aimed to investigate the protective effects of Empa on Cis-induced nephrotoxicity in rats. Male Wistar albino rats were divided into five groups, each of six rats: Sham group (received vehicle for 7 days), Control group (received vehicle for 7 days and Cis injection on day 2), Cis + Empa10 (received 10mg/kg Empa for 7 days and Cis injection on day 2), Cis + Empa30 (received 30mg/kg Empa for 7 days and Cis injection on day 2) and, Empa 30 (received 30mg/kg Empa for 7 days). One day after the last injection in each group, rats were weighed and then sacrificed to analyze the hematological, biochemical, and histological parameters. Cis markedly increased levels of inflammatory parameters such as renal tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, and myeloperoxidase (MPO) activity. Notably, malondialdehyde (MDA), blood urea nitrogen (BUN), and creatinine levels were enhanced after Cis administration. Also, the chemotherapeutic agent significantly reduced antioxidant indicators such as renal catalase (CAT), glutathione peroxidase (GpX), and superoxide dismutase (SOD). Furthermore, histopathological examinations also revealed severe renal damage following Cis treatment which was improved by Empa administration. Empa treatment at both doses (10 mg/kg and 30 mg/kg) reversed Cis-induced changes in all the above renal parameters. In conclusion, Empa has protective effects on Cis-induced nephrotoxicity by inhibition of oxidative stress and inflammation.
顺铂(Cis)是一种用于多种癌症治疗的铂类抗肿瘤药物。该药物可通过诱导氧化应激和炎症反应,导致急性肾损伤(AKI),进而引发肾毒性。恩格列净(Empa)是一种新开发的钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂,已被批准用于治疗2型糖尿病患者。除了具有降血糖作用外,恩格列净还具有抗炎和抗氧化特性。本研究旨在探讨恩格列净对顺铂诱导的大鼠肾毒性的保护作用。将雄性Wistar白化大鼠分为五组,每组六只:假手术组(连续7天接受赋形剂)、对照组(连续7天接受赋形剂,并在第2天注射顺铂)、顺铂+恩格列净10组(连续7天接受10mg/kg恩格列净,并在第2天注射顺铂)、顺铂+恩格列净30组(连续7天接受30mg/kg恩格列净,并在第2天注射顺铂)以及恩格列净30组(连续7天接受30mg/kg恩格列净)。在每组最后一次注射后一天,对大鼠进行称重,然后处死,以分析血液学、生化和组织学参数。顺铂显著提高了炎症参数水平,如肾肿瘤坏死因子-α(TNF-α)、白细胞介素(IL)-1β和髓过氧化物酶(MPO)活性。值得注意的是,顺铂给药后丙二醛(MDA)、血尿素氮(BUN)和肌酐水平升高。此外,化疗药物显著降低了抗氧化指标,如肾过氧化氢酶(CAT)、谷胱甘肽过氧化物酶(GpX)和超氧化物歧化酶(SOD)。此外,组织病理学检查还显示,顺铂治疗后肾脏出现严重损伤,而恩格列净给药可改善这种损伤。两种剂量(10mg/kg和30mg/kg)的恩格列净治疗均可逆转顺铂诱导的上述所有肾脏参数变化。总之,恩格列净通过抑制氧化应激和炎症反应,对顺铂诱导的肾毒性具有保护作用。